登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies
ClinicalTrials.gov 上登记的一项淋巴瘤开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06909474,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Relapsed within 12 months after achieving CR with first-line induction therapy.
入选标准第 3 条
Failure to achieve CR or relapse after ≥2 lines of chemotherapy.
入选标准第 4 条
Refractory to ≥2 lines of chemotherapy, primary resistance, or relapse post-HSCT.
入选标准第 8 条
Renal: Serum creatinine ≤2.0×ULN.
入选标准第 10 条
Hepatic: ALT/AST ≤3.0×ULN (≤5.0×ULN if liver involvement); total bilirubin ≤2.0×ULN.
入选标准第 11 条
HBV DNA > ULN (if HBsAg+ or HBcAb+).
排除标准第 9 条
HCV RNA > ULN (if HCV Ab+).
排除标准第 10 条
At least one bidimensionally measurable lesion per Lugano 2014 criteria: nodal lesions >1.5 cm in long axis; extranodal lesions >1.0 cm in long axis.
入选标准第 7 条
HIV+, syphilis+, or active tuberculosis.
排除标准第 11 条
Prior Malignancy: Within 5 years, except for cured cervical carcinoma in situ, basal/squamous skin cancer, localized prostate cancer, or ductal carcinoma in situ.
排除标准第 18 条
Pregnancy/Lactation: Pregnant, breastfeeding, or planning pregnancy within 1 year post-CAR-NK infusion.
排除标准第 20 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);日常活动能力。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06909474,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
T-ALL Patients: Bone marrow morphology during screening shows ≥5% blasts/immature lymphocytes and/or flow cytometry confirms minimal residual disease (MRD)+, and meets any of the following: Refractory to ≥2 cycles of standard induction chemotherapy (failure to achieve CR). Relapsed within 12 months after achieving CR with first-line induction therapy. Failure to achieve CR or relapse after ≥2 lines of chemotherapy. Relapse after hematopoietic stem cell transplantation (HSCT). T-cell Lymphoma Patients: Confirmed diagnosis of T-lymphoblastic lymphoma (T-LBL) or T-cell non-Hodgkin lymphoma (including but not limited to: peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), extranodal NK/T-cell lymphoma (ENKL), T-cell prolymphocytic leukemia (T-PLL), adult T-cell leukemia/lymphoma (ATLL), mycosis fungoides/Sézary syndrome (MF/SS) stage IIB or higher), and meets both: At least one bidimensionally measurable lesion per Lugano 2014 criteria: nodal lesions >1.5 cm in long axis; extranodal lesions >1.0 cm in long axis. Refractory to ≥2 lines of chemotherapy, primary resistance, or relapse post-HSCT. Cardiac: Left ventricular ejection fraction (LVEF) ≥50% by echocardiography; no significant ECG abnormalities. Renal: Serum creatinine ≤2.0×ULN. Hepatic: ALT/AST ≤3.0×ULN (≤5.0×ULN if liver involvement); total bilirubin ≤2.0×ULN. Pulmonary: Oxygen saturation ≥92% (room air). 7.No Contraindications: To leukapheresis, venipuncture, or cell collection. 8.No Severe Psychiatric Disorders. 9.Contraception: Agreement to use effective contraception from informed consent until 1 year post-CAR-NK infusion (for patients of childbearing potential).排除标准:Exclusion Criteria:
Prior CAR-NK therapy or genetically modified cell therapy. Active CNS involvement at screening (prior CNS involvement with resolved status post-treatment is allowed). Recent Anticancer Therapy: Chemotherapy, targeted therapy, or investigational drugs within 2 weeks or 5 half-lives prior to screening. Radiotherapy within 2 weeks prior to screening. Active/Uncontrolled Infection: Within 1 week prior to screening. Cerebrovascular Event or Seizure: Within 6 months prior to screening. Viral Infections: HBV DNA > ULN (if HBsAg+ or HBcAb+). HCV RNA > ULN (if HCV Ab+). HIV+, syphilis+, or active tuberculosis. Cardiac Disease: NYHA Class III/IV congestive heart failure. Myocardial infarction or CABG ≤6 months prior. Clinically significant ventricular arrhythmia or unexplained syncope (excluding vasovagal/dehydration-related). Severe cardiomyopathy. Active/Uncontrolled Autoimmune Disease. Prior Malignancy: Within 5 years, except for cured cervical carcinoma in situ, basal/squamous skin cancer, localized prostate cancer, or ductal carcinoma in situ. Live Vaccination: Within 4 weeks prior to screening. Pregnancy/Lactation: Pregnant, breastfeeding, or planning pregnancy within 1 year post-CAR-NK infusion. Other: Investigator-determined ineligibility.
引自 ClinicalTrials.gov, NCT06909474, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06909474,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。